Squarepoint Ops LLC trimmed its position in C4 Therapeutics, Inc. (NASDAQ:CCCC – Free Report) by 58.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 57,117 shares of the company’s stock after selling 79,710 shares during the quarter. Squarepoint Ops LLC owned 0.08% of C4 Therapeutics worth $264,000 at the end of the most recent reporting period.
Other large investors have also modified their holdings of the company. Vanguard Group Inc. increased its holdings in C4 Therapeutics by 46.0% in the 1st quarter. Vanguard Group Inc. now owns 2,920,028 shares of the company’s stock valued at $23,857,000 after buying an additional 920,627 shares during the period. Acadian Asset Management LLC boosted its position in shares of C4 Therapeutics by 415.8% during the 2nd quarter. Acadian Asset Management LLC now owns 113,436 shares of the company’s stock valued at $524,000 after acquiring an additional 91,443 shares in the last quarter. Bank of New York Mellon Corp bought a new stake in C4 Therapeutics in the second quarter valued at about $881,000. Hennion & Walsh Asset Management Inc. acquired a new position in C4 Therapeutics in the second quarter worth about $660,000. Finally, Entropy Technologies LP bought a new position in C4 Therapeutics during the first quarter worth about $126,000. 78.81% of the stock is currently owned by institutional investors and hedge funds.
C4 Therapeutics Trading Up 3.0 %
Shares of C4 Therapeutics stock opened at $5.46 on Friday. The stock has a market capitalization of $378.60 million, a price-to-earnings ratio of -2.87 and a beta of 3.04. The firm’s 50-day moving average price is $5.97 and its two-hundred day moving average price is $5.98. C4 Therapeutics, Inc. has a 1-year low of $1.06 and a 1-year high of $11.88.
Wall Street Analysts Forecast Growth
Separately, BMO Capital Markets reiterated an “outperform” rating and issued a $20.00 price objective on shares of C4 Therapeutics in a research note on Tuesday, August 6th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, C4 Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $10.50.
Read Our Latest Analysis on C4 Therapeutics
C4 Therapeutics Profile
C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.
Featured Articles
- Five stocks we like better than C4 Therapeutics
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- 3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
- Why Are Stock Sectors Important to Successful Investing?
- Autodesk Named a “Top Pick” by Morgan Stanley—Is It Time to Buy?
- Health Care Stocks Explained: Why You Might Want to Invest
- 4 Quirky ETFs With Big Potential for Impressive Gains
Receive News & Ratings for C4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.